In vivo study, isoliquiritigenin reverses LPS-induced cognitive deficits, promotes the expression of PSD-95, BDNF, and synaptophysin, and restrains the secretion of CCL3, TNF-α, IL-1β, and IL-6 in hippocampus from LPS-stimulated rats via increasing GSK-3β phosphorylation and Nrf2, HO-1, NQO1 expression, as well as suppressing the protein expression of NF-κB (136). The gene discussed is TNF; the disease is Cognitive impairment.